Instil Bio, Inc. $TIL

What the company doesAI summary of filing

Instil Bio is a pre-revenue biotechnology company focused on identifying and advancing therapeutic opportunities. The company announced in January 2026 that its wholly owned subsidiary, Axion Bio, discontinued development of AXN-2510, a bispecific antibody for solid tumor cancers that had been in-licensed in August 2024, and terminated the related collaboration agreement. Prior to that program, the company pursued development of cell therapies, including a proprietary folate receptor alpha co-stimulatory antigen receptor tumor infiltrating lymphocyte cell therapy for cancer treatment. Instil Bio currently has no product candidate in active development and is actively seeking to in-license or acquire novel therapeutic candidates in diseases with significant unmet medical need. The company has incurred significant losses since inception, identified substantial doubt about its ability to continue as a going concern, and expects to incur losses for the foreseeable future. [10-K 2026-03-27]